LONDON, November 16, 2017 /PRNewswire/ --
See Prospects for Capsule Endoscopy, Drug Delivery and Patient Monitoring in North America, South America, Europe, Asia-Pacific and the Rest of the World
Discover How to Stay Ahead:
Our 133-page report provides 129 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Smart Pill market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects:
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets:
Along with revenue prediction for the overall world market, there are forecasts for 3 Smart Pill Applications in the report at a global level:
Global Smart Pill Market by Application:
• Capsule Endoscopy
• Drug Delivery
• Patient Monitoring
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 major regional and 17 major national markets:
• North America:
• The US
• South America:
• Rest of South America
• The UK
• Rest of Europe
• Rest of Asia-Pacific
• Middle East:
• Other Countries (Rest of World)
The report also includes profiles and for some of the leading companies in the Smart Pill market, with a focus on this segment of these companies' operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, the US, the UK and the APAC region in particular, will continue to achieve high revenue growth to 2027.
Leading companies and the potential for market growth:
Overall world revenue for Smart Pill will surpass $2.4bn in 2017, our work calculates. We predict strong revenue growth through to 2027.
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Smart Pill Market report helps you:
In summary, our 133-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the Smart Pill market, with forecasts for 3 applications and 6 key regional and 17 major national markets - See forecasts for the Smart Pill market in North America, South America, Europe, Asia-Pacific, the Middle east and Africa, as well as the US, Canada, Mexico, Brazil, Argentina, Paraguay, Bolivia, Germany, France, the UK, Italy, France, Japan, China, India, Thailand and Australia.
• What stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market - including company profiles for some of the major companies involved in the Smart Pill market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else:
With our newly updated report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Get our report today Smart Pill Market World Market Forecast 2017-2027: See Prospects for Capsule Endoscopy, Drug Delivery and Patient Monitoring in North America, South America, Europe, Asia-Pacific and the Rest of the World.
To request a report overview of this report please contact Sara Peerun at firstname.lastname@example.org (+44-(0)-20-7336-6100) or refer to our website:
Companies Mentioned in this Report
Amarin Corp. Plc
Array BioPharma, Inc.
Associates Of Cape Cod Inc.
Astex Pharmaceuticals Inc.
Bayer HealthCare AG
Bayer Schering Pharma Aktiengesellschaft
BioLife Solutions, Inc.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Co.
Cardinal Health, Inc.
Chugai Pharmaceutical Co., Ltd.
CK Life Sciences International (Holdings), Inc.
Consensys Imaging Service Inc.
Cornerstone Research & Development Inc.
Crescendo Bioscience, Inc.
CTI BioPharma Corp.
Deroyal Industries Inc.
Domain Therapeutics SA
Emd Millipore Corporation
Emd Serono Inc.
Endo International Plc
GE Healthcare LTD
Henry Schein, Inc.
Janssen Biotech, Inc.
JHL Biotech, Inc.
Johnson & Johnson
Laboratory Corp. of America Holdings
Lombard Medical, Inc.
Lonza Group AG
Medline Industries Inc.
Motion Picture And Television Fund
Myriad Genetics, Inc.
Neptune Technologies & Bioresources, Inc.
Nexvet Biopharma PLC
Northwell Health Inc.
Opexa Therapeutics, Inc.
Otsuka Pharmaceutical Co. Ltd.
Owens & Minor, Inc.
Panacos Pharmaceuticals, Inc.
PELICAN HEALTHCARE LTD
Pharma Mar SA
Polymer Technology Systems Inc.
Quest Diagnostics, Inc.
Smith & Nephew Plc
Spectrum Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc.
Windtree Therapeutics, Inc.
Organisations Mentioned in this Report
European Medicines Agency
Food and Drug Administration (U S)
Ministry of Health, Labor and Welfare
National Cancer Institute
National Health Service (UK)
To see a report overview please email Sara Peerun on email@example.com